Mechanism of action: Pramlintide reduces postprandial blood sugar by mimicking the effects of natural pancreatic amyloid polypeptide, especially for patients who cannot effectively control blood sugar using insulin alone or in combination with other hypoglycemic drugs.

Pramlintide is an analogue of  amylin ,a small peptide hormone that is released into the bloodstream by the β-cells of the pancreas along with insu.lin, after a meal.Like insu.lin, amylin is completely absent in individuals with Type I diabetes.

Pramlintide Benefits:
Reduction in glycated hemoglobin and weight loss have been shown in insu.lin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.
By augmenting endogenous amylin, pramlintide aids in the cellular absorption and regulation of blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1), and inhibiting inappropriate secretion of glucagon, a catabolic hormone that opposes the effects of insu.lin and amylin. Pramlintide also has effects in raising the acute first-phase insu.lin response threshold following a meal.